BioSpace News Archive

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has completed patient enrollment in its Phase 1 trial evaluating the safety and tolerability of SBP-101 when used in combination with standard of care agents gemcitabine and nab-paclitaxel for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA)

Cardiac biomarkers are also called cardiac markers. In a condition when the heart is damaged or stressed, cardiac biomarkers are released into the blood.

Based on therapeutic need, flexible drug formulation can be designed to provide immediate release, delayed release, or sustained release.

A laboratory peristaltic pumps allow fluids to be pumped through a flexible tube that is wrapped around a rotating roller in the pump head which squeezes the liquid out of the tube with compression force.

Ophthalmic corticosteroids are used to prevent permanent damage to the eye, which may occur with certain eye problems.

Semi-quantitative antibody testing is the molecular biology technique that quantitates particular antibodies in a sample.

Funds will support ongoing research & development and further business development

Merieux Equity Partners, IRDI Soridec Gestion and M Capital Partners have joined a Series A financing round into Cell-Easy – a novel French pharmaceutical laboratory specialized in the development and manufacturing of novel cell therapies, for preclinical and clinical studies.

Follows very successful 2020, with five major exits/listings: Promedior, KaNDy, Inflazome, Enterprise Therapeutics and Dyne Therapeutics

Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis, announced that the Centers for Medicare and Medicaid Services has increased Ambulatory Surgery Center reimbursement for the mild® Procedure.